Shares of Novo Nordisk Inc. (NYSE: NVO) are trading lower Tuesday after a new study raised concerns about a potential link ...

Financial Stability: Eli Lilly's balance sheet is more robust, with debt making up only 4% of equity, considerably less than ...

The drug candidate, trevogrumab, in combination with Novo Nordisk's popular obesity drug Wegovy, chemically known as semaglutide, helped patients preserve muscle and increase fat loss in patients, ...

Novo Nordisk was Europe's most valuable company, with a big lead on obesity drugs with its runaway hits Ozempic and Wegovy.

The global weight-loss drug market is experiencing exceptional growth, projected to expand from around $144.6 billion in 2023 ...

Novo Nordisk (NVO) makes Ozempic, the best-known GLP-1 drug out today. And until quite recently, the Danish pharma giant ...

Novo Nordisk continues to deliver strong revenue, profit growth, and high economic profitability. Read why I rate NVO stock a ...

With as much as $17 billion in sales in 2024, it shows no signs of slowing down, much to the delight of its Danish manufacturer, Novo Nordisk A/S ... with future stock performance over the ...

Novo Nordisk stated the leadership change was driven by market challenges and its declining stock performance. While the CEO transition may reassure investors, BMO Capital remains skeptical about ...

Novo Nordisk's stock is still up more than 250% since Jørgensen ... a new CEO following the foundation's request, recent market challenges and the steep decline in the company's share price.